Full Text
HTA34 Quo Vadis Benefit Assessment for Orphan Drugs in Germany: The End of the Exception?

Abstract

Authors

L Weiner R Khonsari S Walzer

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×